Disease, Disability, and Injury Prevention and Control Special Emphasis Panel (SEP): Initial Review, 9481 [2016-03988]
Download as PDF
Federal Register / Vol. 81, No. 37 / Thursday, February 25, 2016 / Notices
Contact Person for More Information:
Paul J. Middendorf, Ph.D., Designated
Federal Officer, NIOSH, CDC, 2400
Century Parkway NE., Mail Stop E–20,
Atlanta, GA 30345, telephone 1 (888)
982–4748; email: wtc-stac@cdc.gov.
The Director, Management Analysis
and Services Office, has been delegated
the authority to sign Federal Register
Notices pertaining to announcements of
meetings and other committee
management activities, for both the
Centers for Disease Control and
Prevention, and the Agency for Toxic
Substances and Disease Registry.
Claudette Grant,
Acting Director, Management Analysis and
Services Office, Centers for Disease Control
and Prevention.
Clifton Road NE., Mailstop E60, Atlanta,
Georgia 30333, Telephone: (404) 718–
8833.
The Director, Management Analysis
and Services Office, has been delegated
the authority to sign Federal Register
notices pertaining to announcements of
meetings and other committee
management activities, for both the
Centers for Disease Control and
Prevention and the Agency for Toxic
Substances and Disease Registry.
Catherine Ramadei,
Acting Director, Management Analysis and
Services Office, Centers for Disease Control
and Prevention.
[FR Doc. 2016–03988 Filed 2–24–16; 8:45 am]
BILLING CODE 4163–18–P
[FR Doc. 2016–03932 Filed 2–24–16; 8:45 am]
BILLING CODE 4163–18–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Disease Control and
Prevention
Centers for Disease Control and
Prevention
mstockstill on DSK4VPTVN1PROD with NOTICES
Disease, Disability, and Injury
Prevention and Control Special
Emphasis Panel (SEP): Initial Review
In accordance with Section 10(a)(2) of
the Federal Advisory Committee Act
(Pub. L. 92–463), the Centers for Disease
Control and Prevention (CDC)
announces a meeting for the initial
review of applications in response to
Funding Opportunity Announcement
(FOA) CK16–006, Research on
Technical Improvement of Personal
Protective Equipment (PPE) to be used
in Healthcare Settings for Infection
Control, including Ebola and other
Emerging Pathogens.
Time and Date: 10:00 a.m.–5:00 p.m.,
EST, March 17, 2016 (Closed).
Place: Teleconference.
Status: The meeting will be closed to
the public in accordance with
provisions set forth in Section
552b(c)(4) and (6), Title 5 U.S.C., and
the determination of the Director,
Management Analysis and Services
Office, CDC, pursuant to Public Law 92–
463.
Matters for Discussion: The meeting
will include the initial review,
discussion, and evaluation of
applications received in response to
‘‘Research on Technical Improvement of
Personal Protective Equipment (PPE) to
be used in Healthcare Settings for
Infection Control, including Ebola and
other Emerging Pathogens’’, CK16–006.
Contact Person for More Information:
Gregory Anderson, M.S., M.P.H.,
Scientific Review Officer, CDC, 1600
VerDate Sep<11>2014
18:07 Feb 24, 2016
Jkt 238001
Clinical Laboratory Improvement
Advisory Committee, Centers for
Disease Control and Prevention:
Notice of Charter Renewal
This gives notice under the Federal
Advisory Committee Act (Pub. L. 92–
463) of October 6, 1972, that the Clinical
Laboratory Improvement Advisory
Committee, Centers for Disease Control
and Prevention (CDC), Department of
Health and Human Services (HHS), has
been renewed for a 2-year period
through February 19, 2018.
For information, contact William R.
MacKenzie M.D., Designated Federal
Officer, Clinical Laboratory
Improvement Advisory Committee,
1600 Clifton Road, NE., Mailstop F–11,
Atlanta, Georgia 30333, telephone 404–
498–6297 or via email at wrm0@cdc.gov.
The Director, Management Analysis
and Services Office, has been delegated
the authority to sign Federal Register
notices pertaining to announcements of
meetings and other committee
management activities, for both the
Centers for Disease Control and
Prevention and the Agency for Toxic
Substances and Disease Registry.
Claudette Grant,
Acting Director, Management Analysis and
Services Office, Centers for Disease Control
and Prevention.
[FR Doc. 2016–03927 Filed 2–24–16; 8:45 am]
BILLING CODE 4163–18–P
PO 00000
Frm 00063
Fmt 4703
Sfmt 4703
9481
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Medicare & Medicaid
Services
[CMS–3322–FN]
Medicare and Medicaid Programs:
Continued Approval of the American
Association for Accreditation of
Ambulatory Surgery Facilities Rural
Health Clinic Accreditation Program
Centers for Medicare &
Medicaid Services, HHS.
ACTION: Final notice.
AGENCY:
This final notice announces
our decision to approve the American
Association for Accreditation of
Ambulatory Surgery Facilities
(AAAASF) for continued recognition as
a national accrediting organization for
Rural Health Clinics (RHCs) that wish to
participate in the Medicare or Medicaid
programs.
DATES: This final notice is effective
March 23, 2016 through March 23, 2022.
FOR FURTHER INFORMATION CONTACT:
Monda Shaver, (410) 786–3410, or
Patricia Chmielewski, (410) 786–6899.
SUPPLEMENTARY INFORMATION:
SUMMARY:
I. Background
A healthcare provider may enter into
an agreement with Medicare to
participate in the program as a Rural
Health Clinic (RHC) provided certain
requirements are met. Sections
1861(aa)(1) and 1905(l)(1) of the Social
Security Act (the Act), establish distinct
criteria for facilities seeking designation
as a RHC. Regulations concerning
Medicare provider agreements are at 42
CFR part 489 and those pertaining to the
survey and certification for Medicare
participation of providers and certain
types of suppliers are at 42 CFR part
488. The regulations at 42 CFR part 491,
subpart A specify the conditions that a
provider must meet to participate in the
Medicare program as a RHC.
Generally, to enter into a Medicare
provider agreement, a facility must first
be certified by a state survey agency as
complying with the conditions or
requirements set forth in part 491,
subpart A, of our Medicare regulations.
Thereafter, the RHC is subject to
periodic surveys by a state survey
agency to determine whether it
continues to meet these conditions.
However; there is an alternative to
certification surveys by state agencies.
Accreditation by a nationally recognized
Medicare accreditation program
approved by the Centers for Medicare &
Medicaid Services (CMS) may substitute
for both initial and ongoing state review.
E:\FR\FM\25FEN1.SGM
25FEN1
Agencies
[Federal Register Volume 81, Number 37 (Thursday, February 25, 2016)]
[Notices]
[Page 9481]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2016-03988]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Centers for Disease Control and Prevention
Disease, Disability, and Injury Prevention and Control Special
Emphasis Panel (SEP): Initial Review
In accordance with Section 10(a)(2) of the Federal Advisory
Committee Act (Pub. L. 92-463), the Centers for Disease Control and
Prevention (CDC) announces a meeting for the initial review of
applications in response to Funding Opportunity Announcement (FOA)
CK16-006, Research on Technical Improvement of Personal Protective
Equipment (PPE) to be used in Healthcare Settings for Infection
Control, including Ebola and other Emerging Pathogens.
Time and Date: 10:00 a.m.-5:00 p.m., EST, March 17, 2016 (Closed).
Place: Teleconference.
Status: The meeting will be closed to the public in accordance with
provisions set forth in Section 552b(c)(4) and (6), Title 5 U.S.C., and
the determination of the Director, Management Analysis and Services
Office, CDC, pursuant to Public Law 92-463.
Matters for Discussion: The meeting will include the initial
review, discussion, and evaluation of applications received in response
to ``Research on Technical Improvement of Personal Protective Equipment
(PPE) to be used in Healthcare Settings for Infection Control,
including Ebola and other Emerging Pathogens'', CK16-006.
Contact Person for More Information: Gregory Anderson, M.S.,
M.P.H., Scientific Review Officer, CDC, 1600 Clifton Road NE., Mailstop
E60, Atlanta, Georgia 30333, Telephone: (404) 718-8833.
The Director, Management Analysis and Services Office, has been
delegated the authority to sign Federal Register notices pertaining to
announcements of meetings and other committee management activities,
for both the Centers for Disease Control and Prevention and the Agency
for Toxic Substances and Disease Registry.
Catherine Ramadei,
Acting Director, Management Analysis and Services Office, Centers for
Disease Control and Prevention.
[FR Doc. 2016-03988 Filed 2-24-16; 8:45 am]
BILLING CODE 4163-18-P